TABLE 4.

Treatment-emergent AEs related to study drug by preferred term

Preferred term	No. (%) of subjects receiving the following treatment with a treatment-emergent AE:
	5 mg (n = 12)	50 mg (n = 12)	100 mg (n = 24)	150 mg (n = 12)	450 mg (n = 12)	Placebo (n = 12)
Any AE	0	0	0	2 (16.7)	0	2 (16.7)
Constipation	0	0	0	1 (8.3)	0	0
Nausea	0	0	0	1 (8.3)	0	0
Dizziness	0	0	0	1 (8.3)	0	0
Presyncope	0	0	0	0	0	1 (8.3)
Orthostatic hypotension	0	0	0	0	0	1 (8.3)
Dermatitis	0	0	0	0	0	1 (8.3)